History of Paclitaxel and Oral Paclitaxel – Clinical Data and Future

Ganesh Divekar; Bharat Bhosale; Padmaj Kulkarni

doi:10.4103/ijmpo.ijmpo_139_20

Indian Journal of Medical and Paediatric Oncology, Table of Contents

CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2020; 41(02): 260-263
DOI: 10.4103/ijmpo.ijmpo_139_20

News and Filler

History of Paclitaxel and Oral Paclitaxel – Clinical Data and Future

Ganesh Divekar

Clinical Operations and Medical Services, SIRO Clinpharm Pvt. Ltd., Thane, Maharashtra, India

,

Bharat Bhosale

Department of Medical Oncology, Bombay Hospital and Medical Research Centre, Mumbai, Maharashtra, India

Department of Medical Oncology, Vedant Hospital, Thane, Maharashtra, India

Department of Medical Oncology, Jaslok Hospital and Research Centre, Mumbai, Maharashtra, India

Department of Medical Oncology, Sir H N Reliance Foundation Hospital and Research Centre, Mumbai, Maharashtra, India

Department of Medical Oncology, SL Raheja Hospital, Mumbai, Maharashtra, India

,

Padmaj Kulkarni

Department of Medical Oncology, Deenanath Mangeshkar Hospital, Pune, Maharashtra, India

› Author Affiliations

Abstract

Full Text

References

References
1 Available from: dtp.cancer.gov/timeline/flash/success_stories/S2_Taxol.htm. [Last accessed on 2020 Mar 22]
2 Crown J, O’Leary M. The taxanes: An update. Lancet 2000; 355: 1176-8
3 Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL. et al. Hypersensitivity reactions from taxol. J Clin Oncol 1990; 8: 1263-8
4 Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Eng J Med 1995; 332: 1004-14
5 Finley RS, Rowinsky EK. Patient care issues: The management of paclitaxel-related toxicities. Ann Pharmacother 1994; 28: S27-30
6 Windebank AJ, Blexrud MD, de Groen PC. Potential neurotoxicity of the solvent vehicle for cyclosporine. J Pharmacol Exp Ther 1994; 268: 1051-6
7 Waugh WN, Trissel LA, Stella VJ. Stability, compatibility, and plasticizer extraction of taxol (NSC-125973) injection diluted in infusion solutions and stored in various containers. Am J Hosp Pharm 1991; 48: 1520-4
8 Hidalgo M, Aylesworth C, Hammond LA, Britten CD, Weiss G, Stephenson Jr. J. et al. Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel. J Clin Oncol 2001; 19: 2493-503
9 Dai MS, Chao TC, Chiu CF, Lu YS, Shiah HS, Wu YY. et al. Oral paclitaxel in the treatment of metastatic breast cancer (MBC). J Clin Oncol 2019; 37 (15) 1084
10 Available from: https://www.athenex.com/pipeline/orascovery-platform/. [Last accessed on 17 Apr 2020]
11 Available from: https://clinicaltrials.gov/ct2/show/NCT03326102. [Last accessed on 22 Mar 2020]
12 Umanzor G, Rugo HS, Barrios FJ, Vesallo RH, Chivalan MA, Bejarano S. Oral paclitaxel with encequidar: The first orally administered paclitaxel shown to be superior to IV paclitaxel on confirmed response and survival with less neuropathy: A phase III clinical study in metastatic breast cancer. Presented at the San Antonio Breast Cancer Symposium. San Antonio, Texas: Abstract: GS6-01; 10-14 December 2019
13 Walko CM, Lindley C. Capecitabine: A review. Clin Ther 2005; 27: 23-44
14 Available from: https://www.medscape.com/viewarticle/576969. [Last accessed on 22 Mar 2020]
15 Zhu J, Zeng W, Ge L, Yang X, Wang Q, Wang H. Capecitabine versus 5-fluorouracil in neoadjuvant chemoradiotherapy of locally advanced rectal cancer: A meta-analysis. Medicine (Baltimore) 2019; 98: e15241
16 Cassidy J, Douillard JY, Twelves C, McKendrick JJ, Scheithauer W, Bustová I. et al. Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes’ C colon cancer: The X-ACT trial. Br J Cancer 2006; 94: 1122-9